Perivascular Cell Characterization and Contribution to the Hematopoietic Niche

血管周围细胞特征及其对造血生态位的贡献

基本信息

  • 批准号:
    8164526
  • 负责人:
  • 金额:
    $ 13.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-30 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abstract Comprehending the hemopoietic cell niche environment is important in our understanding of hematopoiesis. It has been hypothesized that mesenchymal stromal cells (MSC) establish the hematopoietic niche, but their identification and characterization in vivo has not been accomplished. Current thinking suggests that MSC are derived from perivascular cells. MSC are known to secrete high amounts of stroma- derived factor-1 (SDF1), a chemokine involved in the recruitment and maintenance of hematopoietic cells. We have created the first SDF1 reporter transgenic vertebrate in a zebrafish and previously shown that high-SDF1 secreting cells were, in fact, perivascular cells and contribute to SDF1-recruitment of hematopoietic cells after adoptive transfer. This model allows, for the first time, the isolation of hematopoietic niche cells a priori. We hypothesize that perivascular cells give rise to MSC in the ex vivo culture expansion setting and establish the hematopoietic cell niche environment in vitro and in vivo. The primary aim of this work is to characterize perivascular cells both biochemically and functionally. In specific AIM 1, we will determine the in vitro properties of perivascular cells isolated from the sdf1:DsRed transgenic zebrafish and in specific AIM 2 we will determine the potential of perivascular cells to support hematopoietic cell expansion in vitro. Prior characterization of MSC has been focused on detection of mesodermal markers and mesodermal differentiation (osteogenesis, vasculogenesis, and adipogenesis). Using isolated and cultured perivascular cells we will verify cell surface markers and differentiate them into mesodermal lineages. Furthermore, we will show that perivascular cells can support the growth/maintenance of hematopoietic cells in vitro. The benefit of utilizing a transgenic zebrafish is the visualization of the perivascular cells in vivo and in specific AIM 3, we will determine the role of perivascular cells in the maintenance of the hematopoietic cell niche in vivo. To determine the functional significance of perivascular cells, we will construct an sdf promoter driven diphtheria toxin receptor transgenic fish that will allow targeted ablation of the perivascular niche cells. This will be followed by adoptive transfer of labeled donor marrow to quantify the effects of perivascular niche ablation on homing using both visual microscopic assays and quantitative homing assays. The experimental approach outlined here wills us to better understand the hematopoietic microenvironment. PUBLIC HEALTH RELEVANCE: Bone marrow transplant is the only curative measure for some pediatric cancers, but carries with it significant risk due to prolonged neutropenia associated with preparative regimen. We will learn how the hematopoietic cells home and interact with the marrow niche cells which provide their support. Understanding this process will allow us to develop new drugs and therapies to allow hematopoietic cell engraftment to occur with increased efficiency thereby decreasing time of neutropenia and ultimately increasing patient survival. Additionally, knowledge form this work may be used to better understand broader disease mechanisms in the field on bone marrow failure including aplastic anemia, Fanconi's anemia, and radiation exposure.
描述(由申请人提供):摘要理解造血细胞生态位环境对于我们理解造血非常重要。据推测,间充质基质细胞(MSC)建立造血生态位,但其在体内的鉴定和表征尚未完成。目前的想法表明,MSC来源于血管周围细胞。已知MSC分泌大量的基质衍生因子-1(SDF 1),一种参与造血细胞募集和维持的趋化因子。我们已经在斑马鱼中创建了第一个SDF 1报告基因转基因脊椎动物,并且先前表明高SDF 1分泌细胞实际上是血管周围细胞,并且有助于过继转移后SDF 1招募造血细胞。该模型允许,第一次,分离造血小生境细胞的先验。我们假设血管周围细胞在体外培养扩增环境中产生MSC,并在体外和体内建立造血细胞生态位环境。 这项工作的主要目的是表征血管周围细胞的生化和功能。在特定的AIM 1中,我们将确定从sdf 1:DsRed转基因斑马鱼分离的血管周围细胞的体外性质,并且在特定的AIM 2中,我们将确定血管周围细胞支持体外造血细胞扩增的潜力。MSC的先前表征集中于中胚层标记物和中胚层分化(骨生成、血管生成和脂肪生成)的检测。使用分离和培养的血管周围细胞,我们将验证细胞表面标记,并将其分化为中胚层谱系。此外,我们将表明,血管周围细胞可以支持造血细胞在体外的生长/维持。 利用转基因斑马鱼的好处是可视化的血管周围的细胞在体内和特定的AIM 3,我们将确定血管周围的细胞在维持造血细胞的生态位在体内的作用。为了确定血管周围细胞的功能意义,我们将构建sdf启动子驱动的白喉毒素受体转基因鱼,其将允许靶向消融血管周围小生境细胞。随后将过继转移标记的供体骨髓,以使用目视显微镜测定和定量归巢测定来定量血管周围龛消融对归巢的影响。本文概述的实验方法将有助于我们更好地了解造血微环境。 公共卫生相关性:骨髓移植是某些儿童癌症的唯一治愈措施,但由于与准备方案相关的长期中性粒细胞减少症,因此具有显著的风险。我们将了解造血细胞如何回家,并与骨髓龛细胞提供支持。了解这一过程将使我们能够开发新的药物和治疗方法,使造血细胞植入效率提高,从而减少中性粒细胞减少的时间,并最终提高患者的生存率。此外,这项工作的知识可以用来更好地了解骨髓衰竭领域更广泛的疾病机制,包括再生障碍性贫血,范可尼贫血和辐射暴露。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Troy C. Lund其他文献

Neurofilament light chain as a biomarker to indicate early activation of cerebral disease in boys with adrenoleukodystrophy
神经丝轻链作为一种生物标志物,用于指示患有肾上腺脑白质营养不良的男孩脑部疾病的早期激活
  • DOI:
    10.1038/s43856-025-00915-6
  • 发表时间:
    2025-05-23
  • 期刊:
  • 影响因子:
    6.300
  • 作者:
    Troy C. Lund;Ashish O. Gupta;Daniel J. Loes;David R. Nascene;Paul J. Orchard
  • 通讯作者:
    Paul J. Orchard
Adrenoleukodystrophy Protein (ALDP) Antibody Formation and Graft Loss in Gene Therapy for Adrenoleukodystrophy
  • DOI:
    10.1182/blood-2022-155852
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Ashish O. Gupta;Paul J. Orchard;Stuti Thakker;Wilaiwan Durose;Carina King;Troy C. Lund
  • 通讯作者:
    Troy C. Lund
Phototherapy Alters the Plasma Metabolite Profile in Infants Born Preterm with Hyperbilirubinemia
光疗改变早产高胆红素血症婴儿的血浆代谢物谱
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Katherine M. Satrom;Jiuzhou Wang;Eric F Lock;Kirsten Snook;Troy C. Lund;Raghavendra B. Rao
  • 通讯作者:
    Raghavendra B. Rao
Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders
关于遗传性代谢障碍造血细胞移植后免疫介导的血细胞减少症的共识意见
  • DOI:
    10.1038/s41409-020-01179-5
  • 发表时间:
    2021-01-13
  • 期刊:
  • 影响因子:
    5.200
  • 作者:
    Ashish O. Gupta;Jaap Jan Boelens;Christen L. Ebens;Joanne Kurtzberg;Troy C. Lund;Angela R. Smith;John E. Wagner;Robert Wynn;Bruce R. Blazar;Paul J. Orchard
  • 通讯作者:
    Paul J. Orchard
Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome
  • DOI:
    10.1016/j.bbmt.2020.08.033
  • 发表时间:
    2021-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Su Han Lum;Paul J. Orchard;Troy C. Lund;Weston P. Miller;Jaap Jan Boelens;Robert Wynn
  • 通讯作者:
    Robert Wynn

Troy C. Lund的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Troy C. Lund', 18)}}的其他基金

Revealing the Mechanisms and Physiology of Peroxisome Transfer in Stem Cell Therapy
揭示干细胞治疗中过氧化物酶体转移的机制和生理学
  • 批准号:
    9889194
  • 财政年份:
    2019
  • 资助金额:
    $ 13.72万
  • 项目类别:
Perivascular Cell Characterization and Contribution to the Hematopoietic Niche
血管周围细胞特征及其对造血生态位的贡献
  • 批准号:
    8680341
  • 财政年份:
    2011
  • 资助金额:
    $ 13.72万
  • 项目类别:
Perivascular Cell Characterization and Contribution to the Hematopoietic Niche
血管周围细胞特征及其对造血生态位的贡献
  • 批准号:
    8323221
  • 财政年份:
    2011
  • 资助金额:
    $ 13.72万
  • 项目类别:
Perivascular Cell Characterization and Contribution to the Hematopoietic Niche
血管周围细胞特征及其对造血生态位的贡献
  • 批准号:
    8473270
  • 财政年份:
    2011
  • 资助金额:
    $ 13.72万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 13.72万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 13.72万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 13.72万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 13.72万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 13.72万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 13.72万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 13.72万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 13.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了